The American Diabetes Association Announces Winners of the Innovation Challenge to Transform Diabetes Care
This challenge Kickstarts additional investments through the new ADA Innovation Fund
CHICAGO, June 21, 2025 /PRNewswire/ -- As the American Diabetes Association® (ADA) celebrates its 85th anniversary, it continues to fuel transformative progress in the fight to end diabetes—and increasingly, obesity. This year's Innovation Challenge, held during the ADA's 85th Scientific Sessions, highlighted bold ideas driving the future of diabetes treatment and support.
Five visionary finalists presented their innovations on the main stage before a panel of expert judges and a live audience. Three outstanding winners were selected for their potential to revolutionize diabetes care: Kihealth, MYNERVA, and Kayothera, INC.
'One of the biggest things we've learned in our 85 years is that in the fight to end diabetes, every new bit of knowledge, every advancement in treatment, every novel idea matters. We're proud to support these innovators as they help shape a future free of diabetes and all its burdens,' said Elle Uh, the ADA's chief strategy officer and chief of staff.
This year's winners and finalists included:
Winner: Kihealth—A diagnostic test to measure the rate of beta cell death through a liquid biopsy, providing patients and clinicians with a clear view of metabolic health and an earlier window into disease development.
Winner: MYNERVA—An AI-driven neuroprosthetic smart sock for diabetes-related neuropathy to reduce pain and regain stability.
Winner: Kayothera, INC—A first-in-class antagonist of the undruggable retinoid pathway to treat and potentially reverse type 2 diabetes.
Finalist: BioDynamik, Inc.—An orthopedic-driven angiogenesis to restore perfusion for the healing of recalcitrant ischemic ulcers.
Finalist: Generated Health—A chatbot combining AI-driven automation and human-like empathy with a simple text-based platform designed to support both patients and health care teams.
The Innovation Challenge occurs at a critical time. Over 38 million Americans live with diabetes and about 125 million live with obesity. To meet these interconnected epidemics head-on, the ADA is launching the ADA Innovation Fund, a venture philanthropy fund designed to advance the ADA's mission by investing in innovative, high-impact companies developing diabetes, obesity, and other comorbidity-related solutions. Leveraging the ADA's 85-year history of funding hundreds of millions of dollars in innovative research grants, these investments aim to continue to accelerate mission-critical scientific breakthroughs, reduce health disparities, and promote sustainable health care solutions.
About the ADA's Scientific Sessions
The ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook ( American Diabetes Association ), Spanish Facebook ( Asociación Americana de la Diabetes ), LinkedIn ( American Diabetes Association ), and Instagram ( @AmDiabetesAssn ). To learn more about how we are advocating for everyone affected by diabetes, visit us on X ( @AmDiabetesAssn ).
View original content to download multimedia: https://www.prnewswire.com/news-releases/the-american-diabetes-association-announces-winners-of-the-innovation-challenge-to-transform-diabetes-care-302487719.html
SOURCE American Diabetes Association
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
The average healthcare stock has a yield of just 1.7%. Medtronic's dividend yield is 3.3%. Alexandria Real Estate Equities' yield is 7.4%. 10 stocks we like better than Medtronic › The healthcare sector isn't exactly known for offering huge yields, with Health Care Select Sector SPDR (NYSEMKT: XLV) offering a yield of just 1.7%. If dividend investors take some time to dig into the sector, however, they can do much better. For example, Medtronic (NYSE: MDT) has a 3.3% yield today, and Alexandria Real Estate Equities (NYSE: ARE) is offering a yield of 7.4%. Here's what you need to know about each of these high-yield healthcare stocks. Medtronic makes medical devices. It is one of the largest competitors in the space, making products across the cardiovascular, neuroscience, medical surgical, and diabetes categories. It has a leading position in each of the areas in which it operates, and it operates on a global scale. That said, the last few years haven't been the best ones for the company. Innovation, which is highly important in the healthcare space, can be lumpy. And given Medtronic's size, the business has become a little cumbersome. Growth has stalled out, and profitability has come under pressure. Investors have focused on the negatives pushing the shares lower and the dividend yield up toward the high end of Medtronic's historical yield range. If you are a dividend investor that thinks in decades and not days, however, this is likely to be an investment opportunity. The company's innovation pipeline is starting to turn into new-product introductions. As new products gain traction, financial performance is likely to improve. And management has been working to streamline the business with cost cuts and a move to refocus on its most profitable operations. To that end, the company is set to spin off its lower-margin diabetes division in 2026. The move is expected to be immediately accretive to earnings, and the dividend policy isn't expected to change. All in, Medtronic is doing what it needs to do to get back on the growth path. And that should support continued dividend increases; the medical device maker only has two years to go before it hits Dividend King status (50+ years of annual dividend increases). June could be an opportune time to buy the stock hand over fist. Alexandria is a real estate investment trust (REIT), which seems pretty far away from healthcare. Its primary focus is on office properties, which also seems a bit removed from healthcare. The key here is that the REIT owns biomedical research facilities, which combine research space and office space in one property. Both are important to each other since the research takes place in specialized space, while the analysis of that research takes place in a normal office environment. Alexandria is one of the largest pure play medical research REITs you can buy. Alexandria counts some of the largest and most important medical research groups as tenants, from both the private side of the equation and the government side. However, like any landlord, the REIT's revenues will be impacted by the occupancy levels of its properties. And those rise and fall over time. Right now, occupancy is relatively weak, dropping to 91.7% at the end of the first quarter of 2025 from 94.6% at the end of 2024. Swings like this happen from time to time, but Wall Street is treating Alexandria as if its dividend is at a material risk of being cut. Only the funds from operations (FFO) payout ratio in the first quarter was a fairly strong 57%. There's room for adversity before a dividend cut would be in order. To be fair, office properties, and particularly highly specialized office properties, tend to have higher operating costs than other real estate assets. But it seems highly likely that Alexandria will manage its way through this weak patch and continue to extend its 15-year streak of annual dividend increases. For income lovers, this healthcare REIT is worth a deep dive in June. The average healthcare stock has an uninspiring dividend yield. But the average is made up of many different companies, some of which actually have very attractive dividend yields. That list includes industry-leading companies like Medtronic and Alexandria Real Estate. You might just want to pick up shares in one, or both, of these high yielders before June is over after you get to know them a little better. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Wall Street Says Supermicro Stock Could Gain 60% in a Year
Super Micro Computer (SMCI) has weathered significant volatility in recent times, with its stock experiencing a rollercoaster ride. After reaching significant highs, the stock experienced steep declines due to a range of concerns, including allegations of accounting irregularities and a delay in filing its financial reports with the SEC. Nonetheless, SMCI stock has made an impressive recovery recently, climbing 50% year-to-date. 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio Dear Tesla Stock Fans, Mark Your Calendars for June 30 Nvidia Is Quickly Approaching a New Record High. Is It Too Late to Buy NVDA Stock? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Supermicro's stock came under heavy pressure following headlines that shook investor confidence. Allegations of accounting irregularities and a delay in filing annual reports sparked concerns about the possibility of delisting from the Nasdaq Exchange. The company eventually filed its financials, avoiding that outcome, but the damage to investor sentiment was already done. Adding to this were disappointing quarterly earnings. For its fiscal Q3 2025, Supermicro reported $4.6 billion in revenue, a 19% increase year-over-year but a 19% drop quarter-over-quarter. The results missed Wall Street's expectations, mainly due to customers holding back purchases amid uncertainty around new AI platform transitions, particularly Nvidia's (NVDA) move from Hopper to Blackwell GPU architecture. These delays contributed to the shortfall in expectations and added further pressure on the stock. These issues, however, now appear to be in the rearview mirror as those delays are beginning to turn into future growth opportunities. As customers resume spending, Supermicro appears poised to regain momentum. Furthermore, Supermicro recently announced a $20 billion partnership with Saudi Arabia-based DataVolt, which significantly boosted its stock. This deal strengthens the company's demand pipeline and will support future growth. Given these positive developments and continued investments in artificial intelligence (AI) infrastructure, SMCI stock is likely to trend higher. The highest price target for Supermicro stock is $70, courtesy of Loop Capital analyst Ananda Baruah. This target implies nearly 60% upside potential from here. Supermicro is well-positioned to benefit from secular tailwinds in the AI infrastructure market. The company specializes in building high-performance server and storage systems, many of which are now tailored specifically for AI workloads. This provides a significant runway for growth, as it strengthens the company's position to capitalize on AI demand. Thanks to the solid demand, over 70% of Supermicro's total revenue is now derived from AI GPU platforms, reflecting that the company could deliver significant growth as investments in AI continue to rise. Further, to meet the growing demand, Supermicro continues to expand its product portfolio. It has ramped up the production of its Data Center Building Block Solutions (DCBBS), which offer energy-efficient systems for next-generation computing. The company continues to roll out new products, including a range of air-cooled and liquid-cooled AI systems and racks. It has broadened its platform support to include AMD's newest AI accelerators. The expansion of SMCI's product portfolio is expected to help drive its market share higher. Supermicro is strengthening its leadership in the high-performance computing space with its technology to reduce environmental impact. The company's direct liquid cooling (DLC) technology helps lower energy costs, a critical factor as AI workloads become increasingly power-hungry. Furthermore, the rollout of its second-generation DLC-2 system will offer improved energy efficiency and thermal performance, which is expected to drive demand. Moreover, Supermicro's DCBBS reduces the time and complexity involved in building modern data centers. As the demand for scalable, plug-and-play infrastructure grows, DCBBS could become a significant growth driver for the company. The growing use of AI, which requires enhanced data center capabilities, will substantially increase demand for Supermicro's products. Supermicro's ability to design and deliver customized hardware solutions will help meet the specific needs of AI-driven workloads, strengthening its competitive positioning. Moreover, its focus on innovation, including energy-efficient green computing products and enhanced production of its DCBBS, positions it well to gain a higher market share. Analysts maintain a 'Moderate Buy' consensus rating on SMCI stock. However, given the strength of its product lineup and the booming demand in the AI and data center spaces, it wouldn't be surprising to see Supermicro's stock push toward the $70 mark in the near future. On the date of publication, Amit Singh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
WIRED
18 minutes ago
- WIRED
If You're a Sucker For Sticky Notes, the Poppin Sticky Memo Ball Is Art
If a messy desk is a sign of genius, I might be one of the smartest people out there. Everywhere I've worked, whether in an office or my own house, I've begun with the purest of intentions to keep my desk clean and clutter-free, only to weigh the time and energy cost of constantly putting things away just to pull them out again the next day. Spoiler alert: Most of the time, it isn't worth it. One of the biggest, ahem, sticking points in my decluttering process is the sheer number of sticky notes I use. Classic Post-It brand notes, sticky notes shaped like flowers, novelty pads, tape flags—all have a place in my office supply arsenal. I write everything by hand, with a pen. And I mean everything. Not only in my paper planner but also on the sticky notes I have in nearly every room of my house. I have them in the kitchen, in my nightstand, in the car. And I always will, as it's been scientifically proven that writing things down boosts learning and memory, since writing by hand activates more wide-ranging connections in the brain. I love my Notes app as much as anyone else, but if I type something into it that I need to do in the future, I not only have to remember that I did so but also hope I titled it with something searchable. If I write it down on a sticky note, I will not only remember, but I can stick it exactly where I know I'll see it. Doctor's office unexpectedly calling while I'm in another room? Sticky note. Reminder for my husband who's still asleep and doesn't have his phone set to silent, so I can't text him? Sticky note. Sticky notes for my kid. Sticky notes for my friends. Sticky notes in my car, in my garage … It's an infallible system. However, the worst offender of sticky note detritus is by far my workstation. If I receive any kind of actionable instruction, whether it's in a meeting, an email, a Slack message, or via a phone call, it's immediately written down on a sticky note and slapped on my planner or, if longer-range, pinned to the wall above my desk, which is lined with felt bulletin board wall tiles from Amazon and currently looks like the pelt of a disappointing piñata. However, I hadn't really thought much about what those notepads were doing for my space visually until I saw the Poppin' Sticky Memo Ball, the 4.5-inch dodecahedron that looks something like a girly soccer ball but is actually a desk ornament you can put to use. This is the sticky note stack made into decor. Back to School Photograph: Kat Merck The Sticky Memo Ball originated not in a boardroom at 3M, nor in the brains of Romy and Michelle, but at Rochester Institute of Technology. Each year, the STEM-focused school holds a design initiative called Metaproject, pairing companies with RIT students to create products focusing on the theme 'Design Is One,' the official philosophy of the school's Vignelli Center for Design Studies. (Named in honor of Italian designers Lella and Massimo Vignelli, the latter of whom is known for his modernist designs incorporating geometric shapes.)
